At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory ...

the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV pregnant individuals at 32 through 36 weeks gestational age for the ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

The HHS chief, who has long argued that vaccines cause autism, dismissed the notion that "better diagnoses, better recognition, or changing diagnostic criteria" are driving up figures. Also, the CDC's ...

RSV vaccines could get broader CDC backing for adults aged 50-59 at risk after an endorsement from an agency's expert panel. Read more here.